Skip to content

Stargardt Disease: An Oral Vitamin A Trial Slowed Lesion Growth, but Questions Remain

Stargardt disease is the most common inherited macular dystrophy. It affects the macula, the part of the retina responsible for sharp central vision, and can cause profound vision loss. There is no approved treatment. A randomized trial published in JAMA Ophthalmology tested an oral medicine called gildeuretinol acetate, a modified form of vitamin A.

How the trial was designed

TEASE-1 was a two-year, double-masked, placebo-controlled trial at seven U.S. clinics, run between 2015 and 2019. Participants were 12 or older, had a clinical diagnosis of Stargardt disease, and had at least one disease-causing variant in the ABCA4 gene. Fifty people were randomized to daily gildeuretinol (14 mg or 24 mg), placebo, or placebo followed by the drug. Researchers also compared results with 54 natural-history cases. The main outcome was how fast areas of atrophy grew on fundus autofluorescence imaging.

What it found

  • Lesions grew 0.182 mm per year with gildeuretinol versus 0.232 mm per year in the untreated group, a 21.6% relative reduction.
  • Looking only at randomized participants, growth was 0.206 versus 0.242 mm per year, a 14.9% relative reduction.
  • Most side effects were mild or moderate and similar between groups. There were no treatment-related serious adverse events, no clinically significant liver problems, and no reported night blindness.

The authors noted that further research is needed to determine whether this difference matters clinically. Several authors reported funding or employment ties to the drug’s developer, Alkeus Pharmaceuticals.

What families should know

  • Do not start vitamin A or other supplements for Stargardt disease on your own; gildeuretinol is an investigational compound that was studied under close medical supervision.
  • Genetic testing helps confirm the diagnosis and may open doors to clinical trials.
  • Low-vision services can make a real difference in daily life.

Our role

At Khanna Vision Institute, when an exam suggests an inherited retinal disease, we refer patients to retina and genetics specialists for diagnosis and trial guidance. For more general eye-health reading, see thousandoakslasik.com.

Source: Safety and Effects of Gildeuretinol Acetate on Retinal Atrophic Lesions in Stargardt Disease: The TEASE-1 Randomized Clinical Trial (JAMA Ophthalmology (PubMed), 10/01/2026). This article is an educational summary written by Khanna Vision Institute and is not a substitute for medical advice.